University of Münster
CRIS@UM
DE | EN

Dr. med. Andrew Berdel

Current affiliations

  • Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)

Publications

A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
Berdel AF, Koch R, Gerss J, Hentrich M, Peceny R, Bartscht T, Steffen B, Bischoff M, Spiekermann K, Angenendt L, Mikesch JH, Kewitz T, Butterfass-Bahloul T, Serve H, Lenz G, Berdel WE, Krug U, Schliemann C (2023)
In: Annals of Hematology, 102, 63-72. doi:10.1007/s00277-022-05025-0
Research article (journal) | Peer reviewed | Published
563P First-in-class CD13-targeted tissue factor tTF-NGR in patients with recurrent or refractory malignant tumours: Safety and pharmacokinetic results of a phase I study
Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Kessler T, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Schmidt H, Lenz G. Mesters R, Berdel WE (2020)
In:  (eds.), . (kein Verlag angegeben). doi:10.1016/j.annonc.2020.08.677
Research article in edited proceedings (conference) | Peer reviewed | Published
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study
Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Stalmann U, Berning B, Kratz-Albers K, Middelberg-Bisping K, Wiebe S, Albring J, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Bormann E, Schmidt H, Lenz G, Kessler T, Mesters RM, Berdel WE (2020)
In: Cancers, 12(6). doi:10.3390/cancers12061488
Research article (journal) | Peer reviewed | Published